
Apollo Hospitals Q1 Results FY26: Q1 PAT Rises 41.81% to ₹432.80 Crore; Revenue Up 14.81% YoY
Q1 Results FY26
Updated: 13 Aug 2025 • 6:44 pm
Posted by:

Apollo Hospitals Q1 Results FY26: Extracts of FY25 & FY26 (Consolidated Figures)
| Particulars | Quarter Ended | |
| 30-06-2025 | 30-06-2024 | |
| Revenue from Operations | ₹5,842.10 | ₹5,085.60 |
| Profit Before Tax (PBT) | ₹892.10 | ₹712.30 |
| Profit After Tax (PAT) | ₹432.80 | ₹305.20 |
(Figures in crores)
Apollo Hospitals Q1 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)
| Particulars | Quarter Ended | |
| 30-06-2025 | 30-06-2024 | |
| Revenue from Operations | ₹2,167.90 | ₹1,936.60 |
| Profit Before Tax (PBT) | ₹578.60 | ₹498.10 |
| Profit After Tax (PAT) | ₹306.90 | ₹251.70 |
(Figures in crores)
Apollo Hospitals Q1 Results FY26 Highlights (Q1 FY26 vs FY25)
- Apollo Hospitals clocked Q1 FY26 consolidated revenue of ₹5,842.10 crores vs ₹5,085.60 crores.
- On the profit front, Apollo Hospitals earned a consolidated PAT of ₹432.80 crore in Q1 FY26. During FY25, the company’s PAT stood at ₹305.20 crore.
- Consolidated PAT rose for the first quarter of FY26, was 41.81% YoY, and revenue rose 14.88% YoY.
- As per the standalone figures, the quarterly PAT of Apollo Hospitals has increased by 21.93%, and revenue has increased by 11.94% YoY.
Apollo Hospitals Share Price Performance
On the opening bell of 13th August 2025, the shares of Apollo Hospitals opened at ₹7,406.00 per share. However, the initial gains are sustained as of now, and Apollo Hospitals shares are trading at ₹7,740.00 per share, higher than their opening price.
Considering the long-term performance, Apollo Hospitals shares have yielded close to -24.06% returns in the past 1 year, and 5-year returns stand at 890.30%. Over the maximum timeframe, the Apollo Hospitals share provided 34.66% returns to investors. However, one must ignore the risk of volatility in the stock market and invest in Apollo Hospitals shares after thorough research.
For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Recent Articles
Finolex Cables Q1 Results FY26: Q1 PAT Falls 33.33% to ₹162.62 Crore; Revenue Up 13.41% YoY
Abbott India Q1 Results FY26: Q1 PAT Rises 11.54% to ₹365.86 Crore; Revenue Up 11.60% YoY
Jyothy Labs Q1 Results FY26: Q1 PAT Falls 4.95% to ₹96.73 Crore; Revenue Up 1.35% YoY
Zydus Lifesciences Q1 Results FY26: Q1 PAT Rises 3.30% to ₹1,466.80 Crore; Revenue Up 5.90% YoY
Bombay Burmah Trading Q1 Results FY26: Q1 PAT Soars 8.28% to ₹240.70 Crore; Revenue Up 8.73% YoY
Alkem Laboratories Q1 Results FY26: Q1 PAT Rises 21.85% to ₹664.26 Crore; Revenue Up 11.19% YoY
Natco Pharma Q1 Results FY26: Q1 PAT Falls 28.09% to ₹480.70 Crore; Revenue Down 2.47% YoY
Recent Articles

Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan vs UTI Master Equity Plan: NAV, Returns and Maturity Status Compared
28 July 2026

Sundaram Long Term Micro Cap Tax Advantage Fund Series III Direct Plan IDCW Payout vs Bank of India Mid Cap Tax Fund Series 1 Direct IDCW: NAV, Returns and Maturity Status Compared
28 July 2026

Reliance Equity Linked Saving Fund - Series I vs Bank of India Mid Cap Tax Fund Series 1 Regular Growth: NAV, Returns and Maturity Status Compared
28 July 2026

Sundaram Long Term Micro Cap Tax Advantage Fund Series III Direct Plan IDCW Payout vs ICICI Prudential Wealth Enhancement Fund: NAV, Returns and Maturity Status Compared
28 July 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan vs UTI Master Equity Plan: NAV, Returns and Maturity Status Compared
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Direct Plan IDCW Payout vs Bank of India Mid Cap Tax Fund Series 1 Direct IDCW: NAV, Returns and Maturity Status Compared
Reliance Equity Linked Saving Fund - Series I vs Bank of India Mid Cap Tax Fund Series 1 Regular Growth: NAV, Returns and Maturity Status Compared
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Direct Plan IDCW Payout vs ICICI Prudential Wealth Enhancement Fund: NAV, Returns and Maturity Status Compared
SBI Long Term Advantage Fund - Series VI IDCW vs Bank of India Mid Cap Tax Fund Series 2 Regular Growth: NAV, Returns and Maturity Status Compared
Popular this week
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan vs UTI Master Equity Plan: NAV, Returns and Maturity Status Compared
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Direct Plan IDCW Payout vs Bank of India Mid Cap Tax Fund Series 1 Direct IDCW: NAV, Returns and Maturity Status Compared
Reliance Equity Linked Saving Fund - Series I vs Bank of India Mid Cap Tax Fund Series 1 Regular Growth: NAV, Returns and Maturity Status Compared
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Direct Plan IDCW Payout vs ICICI Prudential Wealth Enhancement Fund: NAV, Returns and Maturity Status Compared
SBI Long Term Advantage Fund - Series VI IDCW vs Bank of India Mid Cap Tax Fund Series 2 Regular Growth: NAV, Returns and Maturity Status Compared

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





